Quantcast

Latest Serotonin-norepinephrine reuptake inhibitor Stories

2008-07-24 09:01:13

The American Society of Pain Educators (ASPE) announces the launch of an educational Webcast series on chronic pain with leading health specialists and Olympic Games gold medalist and chronic pain sufferer, Nikki Stone. The first in the three-part series, "Keep Moving! Persistent Chronic Pain Doesn't Have to Hold You Back" is available today at www.painawareness.org. The first Webcast addresses the benefits of exercise for individuals with chronic pain and provides practical tips by leading...

2008-07-23 09:00:00

CHARLOTTE, N.C., July 23, 2008 (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase II trial of Droxidopa, alone and in combination with carbidopa, for the treatment of Fibromyalgia. Fibromyalgia is a chronic and debilitating condition that is characterized by widespread pain and stiffness throughout the body, accompanied by severe fatigue,...

2008-06-27 03:00:35

INDIANAPOLIS, June 27 /PRNewswire-FirstCall/ -- Eli Lilly and Co and Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion supporting the approval of Cymbalta(R) (duloxetine hydrochloride) for the treatment of Generalised Anxiety Disorder (GAD). The positive opinion is based upon the results of five clinical studies -- four double-blind placebo-controlled studies and a...

2008-06-18 09:01:19

WALTHAM, Mass., June 18 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Lexapro is the leading single agent used in anxiety therapy with 11.7 percent and 14.9 percent of first- and second-line patient share, respectively. According to surveyed psychiatrists and primary care physicians (PCPs), Lexapro is distinguished by its superior safety and tolerability profile; physicians specifically...

2008-06-18 03:00:37

Eli Lilly and Co. said the U.S. Food and Drug Administration has approved duloxetine HCl, marketed under the name Cymbalta, for fibromyalgia. The Indianapolis drug maker said Cymbalta is the first serotonin-norepinephrine reuptake inhibitor proven to give relief to patients with the pain disorder. The FDA approval of Cymbalta for the management of fibromyalgia is another important step in the efforts to ensure that people with fibromyalgia will have the availability of effective...

2008-06-17 09:01:13

Eli Lilly and Company has announced that the FDA has approved Cymbalta for the management of fibromyalgia, a chronic widespread pain disorder. Eli Lilly's Cymbalta is said to be the first serotonin-norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia. The fibromyalgia indication represents the second FDA-approved use for Cymbalta for a pain disorder, demonstrating the medication's analgesic effect. The approval marks the fourth disorder...

2008-06-16 09:00:10

The U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company (NYSE: LLY) announced today. Cymbalta is the first serotonin-norepinephrine reuptake inhibitor with proven efficacy for reducing pain in patients with fibromyalgia. The fibromyalgia indication represents the second FDA-approved use for Cymbalta for a pain disorder, demonstrating the medication's analgesic effect....

2008-06-03 09:01:36

WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, despite physicians' desire to prescribe more serotonin/norepinephrine reuptake inhibitors (SNRIs), Forest Laboratories' Lexapro retains leadership among first-line therapies in the treatment of major depression. According to the new report entitled Treatment Algorithms in Major Depression, selective serotonin reuptake...

2007-08-10 06:04:23

The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor. However, all is not lost as Wyeth's greatest commercial opportunity for Pristiq will be gained through indications for depression and menopausal symptoms, although heart and liver safety concerns added to regulatory delays may still limit the drug's potential. The development of Pristiq (desvenlafaxine succinate) for fibromyalgia was terminated during the...

2006-07-19 14:50:00

WASHINGTON (Reuters) - Information about risks to newborns and migraine sufferers linked to some of the world's most widely used antidepressants should be added to the drug labels, the U.S. Food and Drug Administration said on Wednesday. The FDA warned that taking antidepressants known as SSRIs -- including Prozac and Zoloft -- or certain SNRIs in combination with migraine drugs known as triptans could result in a life-threatening condition called serotonin syndrome. It also warned consumers...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related